Sabra Health Care REIT, Inc. (SBRA) Stock Forecast
Data as of May 3, 2026Real Estate · Current price $20.43 (-1.09%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Feb 19, 2026 | Michael Goldsmith | UBS | $21.00 | +2.8% |
| Feb 17, 2026 | Richard Anderson | Cantor Fitzgerald | $21.00 | +2.8% |
| Jan 20, 2026 | Michael Lewis | Truist Financial | $21.00 | +2.8% |
| Dec 15, 2025 | Joe Dickstein | Jefferies | $22.00 | +7.7% |
| Oct 1, 2025 | Richard Anderson | Cantor Fitzgerald | $20.00 | -2.1% |
| Sep 12, 2024 | Nicholas Joseph | Citigroup | $20.00 | -2.1% |
| Sep 3, 2024 | Michael Lewis | Truist Financial | $18.00 | -11.9% |
| Jun 21, 2024 | David Rodgers | Robert W. Baird | $16.00 | -21.7% |
| May 15, 2024 | Nicholas Yulico | Scotiabank | $15.00 | -26.6% |
| May 31, 2023 | Omotayo Okusanya | Credit Suisse | $13.00 | -36.4% |
| Dec 27, 2021 | Michael R Lewis | Truist Financial | $16.00 | -21.7% |
| Aug 24, 2021 | Jonathan Petersen | Jefferies | $19.00 | -7.0% |
| May 4, 2021 | Daniel Bernstein | Capital One Financial | $20.00 | -2.1% |
Top Analysts Covering SBRA
SBRA vs Sector & Market
| Metric | SBRA | Real Estate Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.56 | 2.59 | 2.41 |
| Analyst Count | 9 | 8 | 18 |
| Target Upside | +3.7% | +42.4% | +14.9% |
| P/E Ratio | 31.81 | 25.65 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $830M | $872M | $913M | 2 |
| 2027-03-31 | $224M | $226M | $227M | 1 |
| 2027-06-30 | $227M | $229M | $230M | 1 |
| 2027-09-30 | $231M | $233M | $234M | 1 |
| 2027-12-31 | $235M | $237M | $238M | 1 |
| 2028-03-31 | $154M | $156M | $157M | 1 |
| 2028-06-30 | $159M | $160M | $161M | 1 |
| 2028-09-30 | $160M | $161M | $163M | 1 |
| 2028-12-31 | $162M | $164M | $165M | 1 |
| 2029-12-31 | $1.04B | $1.09B | $1.14B | 1 |
| 2030-12-31 | $1.31B | $1.37B | $1.44B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.68 | $0.69 | $0.70 | 4 |
| 2027-03-31 | $0.19 | $0.19 | $0.19 | 1 |
| 2027-06-30 | $0.20 | $0.20 | $0.20 | 1 |
| 2027-09-30 | $0.20 | $0.20 | $0.20 | 1 |
| 2027-12-31 | $0.20 | $0.20 | $0.20 | 1 |
| 2028-03-31 | $0.20 | $0.20 | $0.20 | 1 |
| 2028-06-30 | $0.21 | $0.21 | $0.22 | 1 |
| 2028-09-30 | $0.21 | $0.22 | $0.22 | 1 |
| 2028-12-31 | $0.21 | $0.21 | $0.21 | 1 |
| 2029-12-31 | $0.79 | $0.84 | $0.89 | 1 |
| 2030-12-31 | $0.00 | $0.00 | $0.00 | 0 |
Frequently Asked Questions
What is the analyst consensus for SBRA?
The consensus among 9 analysts covering Sabra Health Care REIT, Inc. (SBRA) is Hold with an average price target of $21.20.
What is the highest price target for SBRA?
The highest price target for SBRA is $22.00, set by Joe Dickstein at Jefferies on 2025-12-15.
What is the lowest price target for SBRA?
The lowest price target for SBRA is $13.00, set by Omotayo Okusanya at Credit Suisse on 2023-05-31.
How many analysts cover SBRA?
9 analysts have issued ratings for Sabra Health Care REIT, Inc. in the past 12 months.
Is SBRA a buy or sell right now?
Based on 9 analyst ratings, SBRA has a consensus rating of Hold (2.56/5) with a +3.7% upside to the consensus target of $21.20.
What are the earnings estimates for SBRA?
Analysts estimate SBRA will report EPS of $0.69 for the period ending 2026-12-31, with revenue estimated at $872M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.